Bears say:
A new class of therapy not yet fully understood or proven, so arguably there is a higher-than-average risk that harmful side effects could emerge.
What? This is adult stem cell technology. The risk of patient rejection is remote because of the nature of the cells.
They are applying a model that works for pharmaceutical drugs (which often involves side effects) to stem cell technology. The risks involved in that model don't apply here to stem cells which have a low change of patient rejection, and because they're natural, stem cells, not drugs, don't present the same category of risk.
The other comments just show an equal amount of cluelessness.
They read like escape clauses because they don't understand the product, let alone the supposed risks.
So just say something non specific: may present challenges, when they have no idea what such challenges might be.
Seriously?
analysis report, page-3
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |